Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights

Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge study <li style="margin-top: